SCHEMBL8102401

SCHEMBL8102401

CCOC(=O)c1cn2c3c(c(F)c(F)c(F)c3c1=O)OCC1(CC1)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.52
HTT P42858 3/20 0.46
TSHR P16473 1/20 0.44
CASP1 P29466 1/20 0.44
HSD17B10 Q99714 3/20 0.35
TP53 P04637 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GSK3B P49841 2/20 0.35
KDM4E B2RXH2 4/20 0.35
ALDH1A1 P00352 4/20 0.35
CYP1A2 P05177 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
HPGD P15428 2/20 0.33
KMT2A Q03164 2/20 0.33
ADRB2 P07550 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12873964 0.91 STAT3 (0.42) STAT3HTTTSHRCASP1HSD17B10
SCHEMBL8092612 0.88 STAT3 (0.41) STAT3HTTTSHRCASP1HSD17B10
SCHEMBL8098008 0.85 STAT3 (0.39) STAT3HTTTSHRCASP1NPSR1
SCHEMBL8086266 0.84 STAT3 (0.47) STAT3HTTHSD17B10KDM4EALDH1A1
SCHEMBL8102351 0.81 STAT3 (0.46) STAT3HTTTSHRCASP1HSD17B10
SCHEMBL8108262 0.79 MAPT (0.41) STAT3HTTNPSR1RAB9AGSK3B
SCHEMBL12873963 0.79 MAPT (0.35) STAT3HTTTP53NPSR1RAB9A
SCHEMBL8098287 0.75 GSK3B (0.49) GSK3B
SCHEMBL1185838 0.74 STAT3 (0.42) STAT3HTTTSHRCASP1HSD17B10
SCHEMBL1186281 0.74 GSK3B (0.51) STAT3HTTTSHRCASP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203459-B1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN SEIYAKU KK (JP) 2016-03-16 EP disclosed
US-8901112-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2014-12-02 US disclosed
US-8901112-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2014-12-02 US disclosed
US-8476261-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2013-07-02 US disclosed
US-8476261-B2 Spirocyclic aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2013-07-02 US disclosed
US-20110034436-A1 SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-02-10 US disclosed
WO-2009035684-A1 SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS ACTIVX BIOSCIENCES, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034436-A1 SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS GSK3A, GSK3B, GSKIP STAT3 1982/4885HTT 4215/4885TSHR 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.